HIVACAT will host in october the world's largest congress on HIV vaccine


The global search for a vaccine that can stop HIV/AIDS is one of the most important scientific pursuits of our time. The effort to discover that ultimate HIV prevention tool is also in one of its most dynamic periods since the epidemic began. A recent report in the Journal of Acquired Immune Deficiency Syndromes (JAIDS) declared that HIV vaccine research today "is at its most promising point in decades." 

This year, the world's leading scientific conference on HIV vaccine science, AIDS Vaccine 2013, will be held 7 - 10 October in Barcelona, Spain. On the agenda will be the latest research on neutralizing antibodies that may protect against a range of HIV strains; new insights into the immune system that may enhance HIV vaccine development and delivery; and new discoveries about an HIV vaccine clinical trial in Thailand, the first to provide modest protection from HIV infection.

With 2.5 million people newly infected by HIV last year, the need for safe and effective HIV prevention strategies - including the ultimate HIV prevention tool, a vaccine - has never been greater.

The AIDS Vaccine 2013 conference program includes more than 400 oral abstract and poster presentations on the latest advances and challenges in AIDS vaccine research, along with daily plenaries, satellites and special sessions with global leaders in HIV science.


AIDS Vaccine 2013 is organized by the Global HIV Vaccine Enterprise and by this year's local conference hosts, the Catalan Program for HIV Vaccine Research HIVACAT, codirected by the Institute for AIDS Research IrsiCaixa and the AIDS and Infectious Diseases Service at Barcelona’s IDIBAPS-Hospital Clínic, in conjunction with ESTEVE, and with the support of “la Caixa” Foundation, the autonomous Catalan government’s Department of Health and the Department of Economy and Knowledge plus the Clinic Foundation at Barcelona’s IDIBAPS-Hospital Clínic.



Official website of the congress: AIDS Vaccine 2013